Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel P2X7 receptor antagonists.

L Alcaraz1, A Baxter, J Bent

  • 1Department of Medicinal Chemistry, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough LE11 5RH, UK. alcaraz@astrazeneca.com

Bioorganic & Medicinal Chemistry Letters
|November 1, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Archean rifts and triple-junctions revealed by gravity modeling of the southern Superior Craton.

Nature communications·2025
Same author

Estimating population mental health effects of the rollout of Universal Credit in the UK using standard and novel Difference-in-Differences analysis, 2009-2019.

Public health·2025
Same author

Nuclear Recoil Calibration at Sub-keV Energies in LUX and Its Impact on Dark Matter Search Sensitivity.

Physical review letters·2025
Same author

Airway topicalization in pediatric anesthesia: An international cross-sectional study.

Paediatric anaesthesia·2023
Same author

First Dark Matter Search Results from the LUX-ZEPLIN (LZ) Experiment.

Physical review letters·2023
Same author

Drug mixtures and infusion technology.

Anaesthesia·2022

Researchers developed new potent P2X(7) receptor antagonists. These compounds inhibit BzATP-mediated pore formation, suggesting a therapeutic role in inflammatory diseases by targeting key immune cells.

Area of Science:

  • Pharmacology
  • Immunology
  • Medicinal Chemistry

Background:

  • The P2X(7) receptor is implicated in inflammatory processes.
  • Its expression is notable in macrophages, mast cells, and lymphocytes.

Purpose of the Study:

  • To synthesize and pharmacologically evaluate novel P2X(7) receptor antagonists.
  • To investigate the potential of these antagonists in treating inflammatory conditions.

Main Methods:

  • Synthesis of a new series of chemical compounds.
  • Pharmacological evaluation using THP-1 cells.
  • Assessment of inhibition of BzATP-mediated pore formation.

Main Results:

  • A new series of potent P2X(7) receptor antagonists were successfully synthesized.

Related Experiment Videos

  • The synthesized compounds demonstrated inhibition of BzATP-induced pore formation in THP-1 cells.

    • Conclusions:

    • The developed P2X(7) antagonists show promise for treating inflammatory diseases.
    • Targeting the P2X(7) receptor offers a potential therapeutic strategy for inflammation.